A Randomized, Double-Blind, Placebo-Controlled, Multi-Centre Study to Assess the Efficacy of PURETHAL Mites Mixture 50,000 AUeq/mL Subcutaneous Immunotherapy in Adult Subjects With Moderate to Severe Allergic Rhinitis/Rhinoconjunctivitis With or Without Asthma Induced by House Dust Mite (HDM)

• PURETHAL Mites 50,000 AUeq/ml (Biological): Biological/Vaccine: Placebo Increasing volumes of placebo, will be administered by subcutaneous injection (starting with 0.05 ml) at weekly intervals till the maintenance dose (0.5 ml) is reached. Subsequently, maintenance dosages, corresponding to 0.5 ml of placebo, are given at 4-weekly intervals
• Biological/Vaccine: Placebo (Biological): Increasing dosages, corresponding to increasing volumes of drug solution (starting with 0.05 ml), will be administered by subcutaneous injection at weekly intervals till the maintenance dose (0.5 ml) is reached. Subsequently, maintenance dosages, corresponding to 0.5 ml of drug solution, are given at 4-weekly intervals.

Primary outcomes

• Primary objective [Last 8 weeks (before end of study) of the intervention.]: To assess clinical efficacy of PM Mixture 50,000 AUeq/mL (0.5 mL) SCIT in subjects suffering from moderate to severe HDM-induced ARC, measured by difference in the average Total Combined Rhinitis Score (TCRS) during the last 8 weeks of one (± 1 month) year treatment, between PM treatment and placebo. Each symptom will be individually graded and then summed to a maximum of 24 points.

Secondary outcomes

• To assess the effect of PM treatment by comparing the average daily Total Nasal Symptom Score (TNSS) between PM and placebo during the last 8 weeks of one (± 1 month) year treatment of subjects with HDM-allergic ARC. [The last 8 weeks of one (± 1 month) year treatment.]: To assess the effect of PM treatment by comparing the average daily Total Nasal Symptom Score (TNSS) between PM and placebo during the last 8 weeks of one (± 1 month) year treatment of subjects with HDM-allergic ARC.

Sex: All, ages: 18 Years to 65 Years

Inclusion Criteria:

1. Prior to screening, subjects need to have signed the current approved Informed Consent Form (ICF).
2. Male or female subjects age 18-65 years at the time of informed consent.
3. Clinical history consistent with moderate-severe HDM allergic rhinitis (with or without asthma) according to the ARIA classification (Allergic Rhinitis and its Impact on Asthma) (Bousquet et al., 2008), for at least one year prior to the first dosing.
4. Subjects should be able and willing to complete daily e-Diaries for a period of 4 weeks during the screening period, 1 week after maintenance visit 7, and for a period of 8 weeks at the end of treatment under the same living conditions.
5. Forced Expiratory Volume 1 (FEV1) \> 70% at Screening.
6. If a subject is asthmatic, asthma must be clinically controlled for at least three months before the screening using inhaled steroids and / or Long Acting Beta Agonists (corresponding to GINA treatment steps 1 -3) and inhaled steroid use should be on a stable, not higher dose than of ≤400 µg budesonide per day or dose-equivalent (≤500 µg beclometasone dipropionate; ≤160 µg ciclesonide;

   ≤250 µg fluticasone propionate; ≤200 µg mometasone furoate). Patients with asthma should use their standard asthma medication throughout the whole study period to ensure their asthma remains controlled.
7. Positive SPT to D. pter and/or D. far (mean wheal diameter ≥ 3 mm, negative control should be \< 2 mm, histamine positive control should be ≥ 3 mm), assessed at Screening.
8. Subjects with a positive NPT for D. pter extract at Screening (Lebel score ≥6 at 10,000 AU/mL, test should be postponed, if baseline score is ≥ 3 or if negative control score is \> 3).
9. Allergen specific serum IgE level for D. pter and/or D. far of \> 0.7 U/mL, assessed at Screening.
10. Subjects need to have an average daily TNSS of at least 8 out of 12 points at baseline, determined according to the daily e-Diary entries during 2 weeks of baseline assessment. Subjects should have a minimum e-Diary entry compliance of 70% for which the average is calculated.
11. Negative serum pregnancy test at screening for women of childbearing potential.
12. Females of childbearing potential must be using highly effective and acceptable methods of birth control (as per the CTFG recommendations) to prevent pregnancy and agree to continue to practice an acceptable method of contraception for the duration of participation in the trial. Contraceptive measures considered adequate are:

    1. combined (estrogen and progestogen containing) hormonal contraception associated with inhibition of ovulation (oral, intravaginal, transdermal)
    2. progestogen-only hormonal contraception associated with inhibition of ovulation (oral, injectable, implantable)
    3. intrauterine device (IUD)
    4. intrauterine hormone-releasing system (IUS)
    5. bilateral tubal occlusion
    6. vasectomised partner
    7. sexual abstinence Waivers to the inclusion criteria will NOT be allowed.

Exclusion Criteria:

1. A clinically relevant history of symptomatic seasonal ARC and/or a positive SPT (mean wheal diameter ≥ 3 mm) caused by an allergen (including animal hair and dander), to which the subject is regularly exposed and/or exposure is overlapping with the e-Diary completion periods at Screening and at the end of treatment.
2. Nasal surgery and/or severe nasal or severe oral disease within 6 months prior to Screening.
3. Patients not adhering to the e-Diary procedure and/or procedure for Rescue Medication use during e-Diary phase.
4. Severe asthma (GINA 2022 treatment steps 4 - 5).
5. Uncontrolled asthma, as defined by any of the following:

   1. Asthma Control Test (ACT) ≤19,
   2. FEV1 ≤70% of predicted value,
   3. Emergency room visit for asthma attack/exacerbation within 6 months prior to screening,
   4. At least 1 hospitalization due to asthma within the last year,
   5. History of intubation/mechanical ventilation due to asthma,
   6. More than 2 courses of oral steroids used for treatment of asthma within the last 6 months prior to Screening,
   7. Daily use of inhaled corticosteroids \>400mcg budesonide or equivalent.
6. History of anaphylaxis with cardio-respiratory symptoms (food allergy, drugs or an idiopathic reaction).
7. Previous treatment with AIT with HDM allergen or a cross-reacting allergen for more than 1 month at the maintenance level within the last 5 years. Initiation of HDM SCIT is acceptable, if treatment has been discontinued before reaching maintenance dose.
8. AIT (subcutaneous, sublingual or oral) with other allergens than HDM within the last 3 months prior to screening or planned during the trial period.
9. Participation in a clinical trial within the last 3 months prior to screening (e.g.

new investigational drug or biological) or during the trial. 10. Any vaccination (including COVID-19) less than 1 week prior to screening, during screening and the up-dosing phase and the TCRS scoring periods. 11. Any immunosuppressive treatment or anti-IgE therapy within the last 6 months prior to the first dosing of the trial drug and during the trial 12. Any treatment with β-adrenergic blockers unless prescribed as per treatment standards to the subject if the medical benefit will prevail the risks upon investigators discretion. 13. Hypersensitivity to any of the other components of the investigational product. 14. Severe immune disorders (including autoimmune diseases) and/or diseases requiring immunosuppressive medication. 15. Active COVID-19 infection at the time of screening or 2 weeks before. 16. Active malignancies or any malignant disease in the last 5 years. 17. A chronic or acute disease that in the opinion of the investigator might place the subject at an additional risk, including but not limited to the following: cardiovascular insufficiency, any severe or unstable lung diseases, endocrine disorders, clinically significant renal or hepatic diseases, haematological disorders, severe atopic dermatitis, other relevant skin diseases (affecting SPT testing areas). 18. Diseases with a contraindication for the use of adrenaline/epinephrine (e.g.

hyperthyroidism, glaucoma). 19. Use of prohibited medication and/or not able to discontinue medications that are prohibited during the specified trial periods. 20. Moderate to severe nasal obstructive disease such as polyps, septum deviation. 21. Clinically significant chronic sinusitis or ocular infection. 22. Female subjects of childbearing potential who are pregnant or lactating. 23. Alcohol, drug, or medication abuse within the past year and during the trial.

24\. Any (expected) lack of cooperation or compliance upon the discretion of the investigator. 25. Severe psychiatric, psychological, or neurological disorders. 26. Employees of the Sponsor, CRO, clinical study site and/or who are 1st grade relatives, or partners of the investigator. 27. Known commitment to an institution by virtue of an order issued either by the judicial or the administrative authorities 28. Expected changes in average HDM exposure during the trial (e.g. new avoidance measures, relocation and holidays or trips lasting more than 10 days during the efficacy assessment period)

• Hans Hoogeveen, Study director, Head of Clinical Development

NIH grants: 2023